Notice of Intent to Sole Source: ERVEBO
Closed Special Notice Posted
This opportunity was awarded. See the award notice from .
- Agency
- Office of the Assistant Secretary for Preparedness and Response Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Washington, District of Columbia, United States
- Points of contact
-
- Yifan Yang yifan.yang@hhs.gov
- Jonathan Gonzalez jonathan.gonzalez@hhs.gov (202) 381-7248
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Biomedical Advanced Research & Development Authority (BARDA) has published a Special Notice indicating its intent to award a sole source contract to Merck Sharp & Dohme LLC for the procurement of up to 1,000,000 licensed doses of ERVEBO, a vaccine for protection against the Zaire ebolavirus (EBOV). This sole source procurement is intended to replace expiring doses in the Strategic National Stockpile and meet the Public Health Emergency Medical Countermeasures Enterprise's (PHEMCE) requirement of 1,130,000 doses.
The purpose of this Special Notice is to inform the public of BARDA's intent to award a hybrid Cost-Plus-Fixed Fee/Firm-Fixed Price contract to Merck for the procurement of ERVEBO doses, vendor managed inventory (VMI) storage, extension of dose expiry, and the development of a new manufacturing process using bioreactors. The Government will consider any responses received by July 24, 2024 that provide clear evidence that competition would be advantageous. The anticipated award date is in Fiscal Year 2024 with an estimated 120-month period of performance. Merck Sharp & Dohme LLC, as the sole manufacturer of ERVEBO, is the only eligible contractor for this procurement.
Notice text
The Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Biomedical Advanced Research & Development Authority (BARDA) intends to use other than full and open competition to award a sole source contract to Merck Sharp & Dohme LLC to procure up to 1,000,000 licensed doses of ERVEBO, a vaccine for protection against EBOV, VMI storage of doses, extending expiry of doses, and develop a new manufacturing process using bioreactors.
Attachments
| File | Type | Posted |
|---|---|---|
| Notice of Intent for ERVEBO.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| J&a ervebo | Limited / Sole Source Justification | |
| Notice of Award: ERVEBO | Award Notice | |
| Notice of Intent to Sole Source: ERVEBO | Special Notice |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity